Audited Standalone & Consolidated Financial result for the Quarter & Year ended March 31, 2026
BHAGERIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bhageria Industries reported strong full-year results with standalone revenue growing 46% to Rs 87,143 Lakhs from Rs 59,716 Lakhs in FY2025. Net profit after tax increased 19% to Rs 5,030 Lakhs from Rs 4,227 Lakhs, with basic EPS at Rs 11.52 versus Rs 9.68 in the prior year. The Board recommended a dividend of Rs 2.50 per share (50% on face value of Rs 5). Standalone Q4 revenue was Rs 26,675 Lakhs, up 45% from Rs 18,366 Lakhs in Q4 FY2025. Auditors issued unmodified (clean) opinions on both standalone and consolidated results. One subsidiary (Bhageria Industries Holding Company W.L.L) was liquidated in November 2025. The Pharma segment continues to incur losses at Rs 549 Lakhs for the year.
The company delivered robust revenue growth exceeding 45% driven by the Chemicals segment, with profit growth of 19% and a clean audit opinion. The dividend payout signals financial health. The stock may see positive reaction given the strong operational performance, though investors should monitor the loss-making Pharma segment.